Skip to main content

Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance

Edited by:
Cristophe Nicot, PhD, Kansas University Medical Center, United States of America

Submission Status: Open   |   Submission Deadline: 31st July 2024

Molecular Cancer is calling for submissions to our Collection on 'Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance.' 

This Collection welcomes submission of Reviews and Correspondence Articles only. 

About the collection

Molecular Cancer is calling for submissions to our Collection on 'Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance.' 

This Collection aims to showcase cutting-edge research in identification, validation, and clinical application of biomarkers that hold promise for accurate cancer diagnosis, prognosis, and prediction of drug resistance. We welcome Correspondences that address this multifaceted role of biomarkers in guiding personalized treatment strategies, improving patient outcomes, and advancing our understanding of cancer biology. Please note that this Collection will not accept any study based on TCGA analyses without independent cohort validation.

Each Correspondence should start with “To the Editor”, include a maximum of 2 tables or figures, a maximum of 15 references and up to 1500 words in text. It should also have two subsections to better delineate the content, Abstract and Results/Discussion. 

This Collection welcomes submission of Correspondence Articles only. 

Image credit: © [M] freshidea /

  1. Metastatic colorectal cancer (mCRC) presents significant challenges in clinical management due to its heterogeneity and variable response to treatment. In this study, we conducted comprehensive small RNA (sRNA...

    Authors: Robin Mjelle, Are K. Kristensen, Tora S. Solheim, Ganna S. Westvik, Hege Elvebakken and Eva Hofsli
    Citation: Molecular Cancer 2024 23:133
  2. TFE3-rearranged renal cell carcinoma (TFE3-rRCC) is a rare but highly heterogeneous renal cell carcinoma (RCC) entity, of which the clinical treatment landscape is largely undefined. This study aims to evaluate a...

    Authors: Junjie Zhao, Yanfeng Tang, Xu Hu, Xiaoxue Yin, Yuntian Chen, Junru Chen, Haoyang Liu, Haolin Liu, Jiayu Liang, Xingming Zhang, Jinge Zhao, Sha Zhu, Yuchao Ni, Zhipeng Wang, Jindong Dai, Zilin Wang…
    Citation: Molecular Cancer 2024 23:132
  3. The clinical heterogeneity of early-stage endometrial cancer (EC) is worthy of further study to identify high-quality prognostic markers and their potential role in aggressive tumor behavior. Mutation of TP53 ...

    Authors: Xiaodan Mao, Xiaoyue Tang, Jingxuan Ye, Shuxia Xu, Yue Wang, Xianhua Liu, Qibin Wu, Xite Lin, Maotong Zhang, Jiangfeng Liu, Juntao Yang and Pengming Sun
    Citation: Molecular Cancer 2024 23:127
  4. Breast cancer (BC) is the most frequent malignant cancer diagnosis and is a primary factor for cancer deaths in women. The clinical subtypes of BC include estrogen receptor (ER) positive, progesterone receptor...

    Authors: Chang-Yun Li, Wanhe Wang, Chung-Hang Leung, Guan-Jun Yang and Jiong Chen
    Citation: Molecular Cancer 2024 23:109
  5. Accurate presurgical prediction of pathological complete response (pCR) can guide treatment decisions, potentially avoiding unnecessary surgeries and improving the quality of life for cancer patients. We devel...

    Authors: Pinli Yue, Fenglong Bie, Jiarun Zhu, Lin-Rui Gao, Zhendiao Zhou, Guangyu Bai, Xiaobing Wang, Ziyi Zhao, Ze-Fen Xiao, Yong Li, Aiping Zhou, Wen-Yang Liu, Yuchen Jiao and Shugeng Gao
    Citation: Molecular Cancer 2024 23:96
  6. The Neurotrophic tyrosine receptor kinase (NTRK) family plays important roles in tumor progression and is involved in tumor immunogenicity. Here, we conducted a comprehensive bioinformatic and clinical analysis t...

    Authors: Congren Wang, Yingying Li, Jinyuan Huang, Huimeng Yan and Bin Zhao
    Citation: Molecular Cancer 2024 23:81
  7. For decades, great strides have been made in the field of immunometabolism. A plethora of evidence ranging from basic mechanisms to clinical transformation has gradually embarked on immunometabolism to the cen...

    Authors: Qin Dang, Borui Li, Bing Jin, Zeng Ye, Xin Lou, Ting Wang, Yan Wang, Xuan Pan, Qiangsheng Hu, Zheng Li, Shunrong Ji, Chenjie Zhou, Xianjun Yu, Yi Qin and Xiaowu Xu
    Citation: Molecular Cancer 2024 23:72
  8. Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical practice poses challenges...

    Authors: Ling Wang, Xin Wang, Xueping Zhu, Lin Zhong, Qingxiu Jiang, Ya Wang, Qin Tang, Qiaoling Li, Cong Zhang, Haixia Wang and Dongling Zou
    Citation: Molecular Cancer 2024 23:66
  9. Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein, we developed a multitarget urine tumor DNA test, UI-Seek, ...

    Authors: Junlong Wu, Yuda Lin, Kaiwei Yang, Xiao Liu, Huina Wang, Tingting Yu, Ran Tao, Jing Guo, Libin Chen, Huanqing Cheng, Feng Lou, Shanbo Cao, Wei Yu, Hailong Hu and Dingwei Ye
    Citation: Molecular Cancer 2024 23:57
  10. the problem in early diagnosis of sporadic cancer is understanding the individual’s risk to develop disease. In response to this need, global scientific research is focusing on developing predictive models bas...

    Authors: Natalia Malara, Maria Laura Coluccio, Fabiana Grillo, Teresa Ferrazzo, Nastassia C. Garo, Giuseppe Donato, Annamaria Lavecchia, Franco Fulciniti, Anna Sapino, Eliano Cascardi, Antonella Pellegrini, Prassede Foxi, Cesare Furlanello, Giovanni Negri, Guido Fadda, Arrigo Capitanio…
    Citation: Molecular Cancer 2024 23:32
  11. Heat shock proteins play crucial roles in various biochemical processes, encompassing protein folding and translocation. HSP90B1, a conserved member of the heat shock protein family, growing evidences have dem...

    Authors: Xiaoliang Huang, Weiming Zhang, Na Yang, Yujie Zhang, Tianyu Qin, Hanyi Ruan, Yan Zhang, Chao Tian, Xianwei Mo, Weizhong Tang, Jungang Liu and Beibei Zhang
    Citation: Molecular Cancer 2024 23:19
  12. Triple negative breast cancer (TNBC) is a heterogeneous group of tumors which lack estrogen receptor, progesterone receptor, and HER2 expression. Targeted therapies have limited success in treating TNBC, thus ...

    Authors: Heba Alkhatib, Jason Conage-Pough, Sangita Roy Chowdhury, Denen Shian, Deema Zaid, Ariel M. Rubinstein, Amir Sonnenblick, Tamar Peretz-Yablonsky, Avital Granit, Einat Carmon, Ishwar N. Kohale, Judy C. Boughey, Matthew P. Goetz, Liewei Wang, Forest M. White and Nataly Kravchenko-Balasha
    Citation: Molecular Cancer 2024 23:17
  13. The tumor microenvironment (TME) is an intricate system comprised of tumor cells and the surrounding cellular and non-cellular components, exerting a pivotal influence on the initiation and progression of tumo...

    Authors: Xinming Su, Chenhao Liang, Ruixiu Chen and Shiwei Duan
    Citation: Molecular Cancer 2024 23:13

Submission Guidelines

Back to top

This Collection welcomes submission of Correspondence Articles only. 

Please read our submission guidelines before submitting your article. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.